Genomic Health (GHDX) : State Farm Mutual Automobile Insurance Co scooped up 57,059 additional shares in Genomic Health during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 317,240 shares of Genomic Health which is valued at $8,565,480.Genomic Health makes up approximately 0.01% of State Farm Mutual Automobile Insurance Co’s portfolio.
Other Hedge Funds, Including , Pacad Investment Ltd. added GHDX to its portfolio by purchasing 2,500 company shares during the most recent quarter which is valued at $67,500. Genomic Health makes up approx 0.01% of Pacad Investment Ltd.’s portfolio.Teacher Retirement System Of Texas boosted its stake in GHDX in the latest quarter, The investment management firm added 308 additional shares and now holds a total of 2,511 shares of Genomic Health which is valued at $72,317.Dekabank Deutsche Girozentrale boosted its stake in GHDX in the latest quarter, The investment management firm added 3,400 additional shares and now holds a total of 17,400 shares of Genomic Health which is valued at $515,910. Genomic Health makes up approx 0.01% of Dekabank Deutsche Girozentrale’s portfolio.
Genomic Health closed down -0.53 points or -1.93% at $26.95 with 4,01,366 shares getting traded on Tuesday. Post opening the session at $27.47, the shares hit an intraday low of $26.76 and an intraday high of $27.5 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Genomic Health reported $-0.18 EPS for the quarter, based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus estimate of $-0.18. The company had revenue of $81.97 million for the quarter, compared to analysts expectations of $81.18 million. The company’s revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.29 EPS.
Genomic Health Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score which it calls a Recurrence Score for invasive breast cancer and colon cancer a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR) in standard tumor pathology specimens to provide tumor-specific information or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.